The FDA is amplifying an effort underway at the medical device distributor Medline, which aims to correct certain ...

Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, lead | Scancell has linked iSCIB1+ to a 69% response ...

The FDA has rejected Replimune’s request for approval of RP1, adding the melanoma drug candidate to the list of assets to ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

Korean preclinical CRO CorestemChemon is expanding its offerings through a partnership with ATG Lifetech, with the goal of bringing pharma clients next-gen non-clinical solutions.

The portable MRI manufacturer Hyperfine has begun rolling out the next generation of its artificial intelligence-equipped scanner-on-wheels, following an FDA green light last month.  | The Fierce ...

Medtronic has secured a new approval in Europe, greatly expanding the reach of its MiniMed 780G pump system—including for ...

The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb girdle ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Concentra Biosciences is living up to its reputation of buying beleaguered biotechs, this time swooping in to grab iTeos ...

The three-year-old spinout from Zimmer Biomet has reached the end of its road. | The three-year-old spinout from Zimmer ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...